

September 15, 2022

The National Stock Exchange of India Ltd.
Corporate Communications Department
"Exchange Plaza", 5th Floor,
Bandra-Kurla Complex, Bandra (East),
Mumbai - 400051

BSE Limited
Corporate Services Department
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai - 400 001

Scrip Symbol: ORCHPHARMA

Scrip Code: 524372

Subject: Submission of weblinks under Regulation 46 and Regulation 62 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: NSE Circular NSE/CML/2022/35 dated 11th July 2022 - Advisory under Regulation 46 and 62 ("the Circular")

Dear Sir(s),

This is in reference to the above captioned subject and NSE Circular NSE/CML/2022/35 dated 11th July 2022 - Advisory under Regulation 46 and 62.

In the matter, we would like to inform you that in accordance to the guidelines issued under the said Circular, Orchid Pharma Limited ("**the Company**") has submitted the website links in excel format with National Stock Exchanges on NEAPS portal.

Enclosed is copy of the said excel sheet in pdf form for your easy reference.

Kindly take the same on your record.

Yours truly,
For Orchid Pharma Limited

MANISH
DHANUKA

Digitally signed by MANISH
DHANUKA
Date: 2022.09.15 16:13:13
+05'30'

Manish Dhanuka
Managing Dhanuka
DIN:00238798

Sl. No.	Particulars as per LODR	Y/N/NA	URL	Remarks
1	(a) Details of business	Y	http://orchidpharma.com/OurBusiness.html	
2	(b) Terms and conditions of appointment of independent directors	Y	http://orchidpharma.com/2016%20Annual%20Report/2016%20Independent%20Directors.pdf	
3	(c) Composition of various committees of board of directors	Y	http://orchidpharma.com/investor_relations/committee.html	
4	(d) Code of conduct of board of directors and senior management personnel	Y	http://orchidpharma.com/2016%20Annual%20Report/2016%20Code%20of%20Conduct%20of%20Directors%20and%20Senior%20Management%20.pdf	
5	(e) Details of establishment of vigil mechanism/ Whistle Blower policy	Y	http://orchidpharma.com/2016%20Annual%20Report/2016%20Whistle%20Blower.pdf	
6	(f) Criteria of making payments to non-executive directors, if the same has not been disclosed in annual report	Y	http://orchidpharma.com/2016%20Annual%20Report/2016%20Non-Executive%20Directors.pdf	
7	(g) Policy on dealing with related party transactions	Y	http://orchidpharma.com/downloads/RPT.pdf	
8	(h) Policy for determining 'material' subsidiaries	Y	http://orchidpharma.com/2016%20Annual%20Report/2016%20Subsidiaries.pdf	
9	(i) Details of familiarization programmes imparted to independent directors including the following details:- (i) Number of programmes attended by independent directors (during the year and on a cumulative basis till date) (ii) Number of hours spent by independent directors in such programmes (during the year and on cumulative basis till date), and (iii) Other relevant details	Y	http://orchidpharma.com/2016%20Annual%20Report/2016%20Independent%20Directors.pdf	
10	(j) The email address for grievance redressal and other relevant details	Y	http://orchidpharma.com/investor_relations	
11	(k) Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances	N	Point number 10 and 11 are same. The URL is http://orchidpharma.com/investor_relations.html	
12	(l) Financial information including: (i) Notice of meeting of the board of directors where financial results shall be discussed (ii) Financial results, on conclusion of the meeting of the board of directors where the financial results were approved (iii) Complete copy of the annual report including balance sheet, profit and loss account, directors report, corporate governance report etc.	Y	http://orchidpharma.com/investor_relations.html	
13	(m) Shareholding pattern	Y	http://orchidpharma.com/investor_relations/shareholding.html	
14	(n) Details of agreements entered into with the media companies and/or their associates, etc.	N	there is no Agreement with Media companies	
15	(o) Schedule of analysts or institutional investors meet and presentations made by the listed entity to analysts or institutional investors. Explanation: For the purpose of this clause 'meet' shall mean group meetings or group conference calls conducted physically or through digital means (oa) Audio or video recordings and transcripts of post earnings/quarterly calls, by whatever name called, conducted physically or through digital means, simultaneously with submission to the recognized stock exchange(s), in the following manner: (i) The presentation and the audio/video recordings shall be promptly made available on the website and in any case, before the next trading day or within twenty-four hours from the conclusion of such calls, whichever is earlier (ii) The transcripts of such calls shall be made available on the website within five working days of the conclusion of such calls	Y	http://orchidpharma.com/investor_relations.html	
16	(p) New name and the old name of the listed entity for a continuous period of one year, from the date of the last name change	N		there has been no change in the name of the company

17	(q) Items published in the newspaper: (a) financial results, as specified in regulation 33, along-with the modified opinion(s) or reservation(s), if any, expressed by the auditor; (b) notices given to shareholders by advertisement.	Y	http://orchidpharma.com/invr_advertisements.html
18	(r) All credit ratings obtained by the entity for all its outstanding instruments, updated immediately as and when there is any revision in any of the ratings.	Y	http://orchidpharma.com/invr_cred_rating.html
19	(s) Separate audited financial statements of each subsidiary of the listed entity in respect of a relevant financial year, uploaded at least 21 days prior to the date of the annual general meeting which has been called to inter alia consider accounts of that financial year.	NA	The company does not have subsidiary company
20	(t) Secretarial compliance report.	Y	http://orchidpharma.com/AnnualSecretarialComplianceReports.html
21	(u) Disclosure of the policy for determination of materiality of events or information	Y	http://orchidpharma.com/AnnualMateriality%20of%20Events%20of%20Information.pdf
22	(v) Disclosure of contact details of key managerial personnel who are authorized for the purpose of determining materiality of an event or information and for the purpose of making disclosures to stock exchange(s)	Y	http://orchidpharma.com/invr_contact.html
23	(w) All such events or information which has been disclosed to stock exchange(s) under regulation 30 of LODR	Y	http://orchidpharma.com/invr_information.aspx
24	(x) Statements of deviation(s) or variation(s)	NA	Company has not made any public issue, right issue or preferential issue
25	(y) Dividend distribution policy by listed entities based on market capitalization	Y	http://orchidpharma.com/Dividend%20Distribution%20Policy.pdf
26	(z) Annual return as provided under section 92 of the Companies Act, 2013 and the rules made thereunder.	Y	http://orchidpharma.com/AnnualReturn.html